0000000000519121

AUTHOR

Eduardo Mansilla

showing 3 related works from this author

New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

2013

Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20…

Lymphomamedicine.medical_treatmentlcsh:MedicineApoptosisnanoparticles; Targeting strategies; LymphomaAggressive lymphomaMice SCIDPharmacologyAntibodies Monoclonal Murine-DerivedMiceDrug Delivery Systems0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesNANOPARTICLESMedicinelcsh:ScienceCD200303 health sciencesMultidisciplinarybiologyNANOPARTICLES; ANTI-CD20; B-CELL MALIGNANCIESnanoparticleANTI-CD20Flow CytometryImmunohistochemistry3. Good healthDrug CombinationsLeukemia030220 oncology & carcinogenesisMonoclonalTargeting strategieFemaleRituximabRituximabHydroxychloroquineResearch Articlemedicine.drugLymphoma B-CellCell Survival03 medical and health sciencesMicroscopy Electron TransmissionAutophagyB-CELL MALIGNANCIESAnimalsTargeting strategies030304 developmental biologyChlorambucilbusiness.industrylcsh:RHydroxychloroquineImmunotherapyAntigens CD20medicine.diseaseDisease Models Animalbiology.proteinChlorambucillcsh:QbusinessPLoS ONE
researchProduct

A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles

2015

Current approaches for the treatment of chronic lymphocytic leukemia (CLL) have greatly improved the prognosis for survival, but some patients remain refractive to these therapeutic regimens. Hence, in addition to reducing the long-term sideeffects of therapeutics for all leukemia patients, there is an urgent need for novel therapeutic strategies for difficult-to-treat leukemia cases. Due to the cytotoxicity of drugs, the major challenge currently is to deliver the therapeutic agents to neoplastic cells while preserving the viability of non-malignant cells. In this study, we propose a therapeutic approach in which high doses of hydroxychloroquine and chlorambucil were loaded into biodegrada…

0301 basic medicineChronic lymphocytic leukemiaxenograft modelchronic lymphocytic leukemia; immune targeted nanoparticles; treatment; xenograft model; Electrical and Electronic Engineering; Materials Science (all)Nanotechnology03 medical and health sciencesTherapeutic approach0302 clinical medicinehemic and lymphatic diseasesmedicineGeneral Materials ScienceElectrical and Electronic EngineeringCytotoxicityCD20immune targeted nanoparticletreatmentChlorambucilbiologybusiness.industryTherapeutic effectHydroxychloroquineCondensed Matter Physicsmedicine.diseaseAtomic and Molecular Physics and OpticsLeukemia030104 developmental biology030220 oncology & carcinogenesisimmune targeted nanoparticlesCancer researchbiology.proteinchronic lymphocytic leukemiaMaterials Science (all)businessmedicine.drugNano Research
researchProduct

Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma.

2010

The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BN…

Pathologymedicine.medical_specialtyCell Survivalhuman/mouse model of Burkitt lymphoma.human lymphomamodel SCID mouseAntineoplastic Agentschemistry.chemical_compoundAntibodies Monoclonal Murine-DerivedMicerituximabimmune system diseasesAnnexinhemic and lymphatic diseasesnanoparticles; rituximab; human lymphoma; model SCID mouseTumor Cells CulturedMedicineAnimalsHumansPharmacology (medical)Propidium iodideGeneral Pharmacology Toxicology and PharmaceuticsCytotoxicityB-LymphocytesChlorambucilDose-Response Relationship Drugbusiness.industrymalignant B cellnanoparticleDrug SynergismGeneral MedicineBiodegradable nanoparticles with drugmedicine.diseaseBurkitt LymphomaLymphomaMice Inbred C57BLLeukemiaDisease Models AnimalDrug CombinationschemistryApoptosisMonoclonalCancer researchNanoparticlesChlorambucilbusinessRituximabmedicine.drugHydroxychloroquine
researchProduct